ME02364B - Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom - Google Patents
Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvomInfo
- Publication number
- ME02364B ME02364B MEP-2016-31A MEP3116A ME02364B ME 02364 B ME02364 B ME 02364B ME P3116 A MEP3116 A ME P3116A ME 02364 B ME02364 B ME 02364B
- Authority
- ME
- Montenegro
- Prior art keywords
- suppressing
- compounds
- cancer agent
- peripheral nerve
- nerve disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010015935 | 2010-01-27 | ||
PCT/JP2011/052077 WO2011093512A1 (en) | 2010-01-27 | 2011-01-26 | Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
EP11705047.6A EP2528598B1 (en) | 2010-01-27 | 2011-01-26 | Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02364B true ME02364B (me) | 2016-06-20 |
Family
ID=43770309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2016-31A ME02364B (me) | 2010-01-27 | 2011-01-26 | Jedinjenja za supresiju poremećaja perifernih nerava indukovanih anti-kancerogenim sredstvom |
Country Status (41)
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9428477B2 (en) * | 2012-04-27 | 2016-08-30 | Nippon Zoki Pharmaceutical Co., Ltd. | Trans-2-decenoic acid derivative and drug containing same |
EP3083686B2 (en) * | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
EA033083B1 (ru) | 2015-05-08 | 2019-08-30 | Такеда Фармасьютикал Компани Лимитед | Циклические соединения |
CN107771076A (zh) | 2015-06-17 | 2018-03-06 | 豪夫迈·罗氏有限公司 | 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
CA3036349A1 (en) * | 2016-09-09 | 2018-03-15 | Takeda Pharmaceutical Company Limited | Cyclic compound having toll-like receptor 4 (tlr4) inhibitory activity |
AU2018328532A1 (en) * | 2017-09-07 | 2020-04-23 | Ningbo Combireg Pharmaceutical Technology Co., Ltd | Pharmaceutical composition of docetaxel conjugate and preparation method |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
ATE106089T1 (de) | 1986-01-09 | 1994-06-15 | Massachusetts Inst Technology | Nukleare faktoren, die mit der regulierung der transkription assoziiert sind. |
US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
US4785000A (en) | 1986-06-18 | 1988-11-15 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US4769372A (en) | 1986-06-18 | 1988-09-06 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
WO1988005083A1 (en) | 1986-12-24 | 1988-07-14 | Whitehead Institute For Biomedical Research | Method of inducible gene expression |
WO1989007614A1 (en) | 1988-02-12 | 1989-08-24 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
DE68910682T2 (de) | 1988-03-01 | 1994-06-01 | Whitehead Biomedical Inst | Aktivierung der nf-kappa b-vorstufe. |
US5506231A (en) | 1989-03-31 | 1996-04-09 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5334618A (en) | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
WO1990011761A1 (en) | 1989-03-31 | 1990-10-18 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy and blindness |
US5059712A (en) | 1989-09-13 | 1991-10-22 | Cornell Research Foundation, Inc. | Isolating aminoarginine and use to block nitric oxide formation in body |
US5158883A (en) | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
WO1992003137A1 (en) | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
US5455279A (en) | 1991-04-19 | 1995-10-03 | The Children's Medical Center Corporation | Regimen method of mediating neuronal damage using nitroglycerine |
WO1992017168A1 (en) | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
US5614560A (en) | 1991-04-04 | 1997-03-25 | Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
ATE182076T1 (de) | 1991-04-19 | 1999-07-15 | Childrens Medical Center | Verfahren zur vorbeugung nmda-rezeptorkomplex- vermittelter neuronaler schäden |
US6071876A (en) | 1991-04-19 | 2000-06-06 | Children's Medical Center Corporation | Method of preventing NMDA receptor complex-mediated neuronal damage |
IL122427A0 (en) * | 1995-06-07 | 1998-06-15 | Sugen Inc | Pharmaceutical compositions and methods for inhibition of adaptor protein/tyrosine kinase interactions |
US20020086368A1 (en) | 1997-10-17 | 2002-07-04 | Genentech Inc | Human toll homologues |
US20020052019A1 (en) | 1997-11-13 | 2002-05-02 | Genentech Inc | Human toll homologue |
US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
PT1887014E (pt) | 1997-10-17 | 2010-07-05 | Genentech Inc | Homëlogos de toll humana |
AU1539499A (en) | 1997-11-25 | 1999-06-15 | Princeton University | Method for preparing adenovirus vectors, vectors so prepared, and uses thereof |
US20080275104A1 (en) | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US20040072138A1 (en) | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
BR9908610A (pt) | 1998-03-09 | 2000-12-05 | Takeda Chemical Industries Ltd | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos |
DE60045033D1 (de) | 1999-08-06 | 2010-11-11 | Takeda Pharmaceutical | Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung |
SE9903930D0 (sv) * | 1999-10-29 | 1999-10-29 | Astra Pharma Inc | Novel compounds and a novel process for their preparation |
CA2400804C (en) | 2000-02-04 | 2009-09-01 | Takeda Chemical Industries, Ltd. | Stable emulsion compositions of cycloalkene derivatives |
EP1283849A2 (en) | 2000-05-25 | 2003-02-19 | Schering Corporation | Human receptor proteins; related reagents and methods |
US6951885B2 (en) | 2000-08-10 | 2005-10-04 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
DE60144570D1 (de) | 2000-10-18 | 2011-06-16 | Takeda Pharmaceutical | Verfahren zur herstellung von optisch aktiven sulfonamiden und zwischenprodukte zur deren synthese |
CA2398613C (en) | 2000-11-30 | 2006-09-12 | Tokuyama Corporation | Substrate and production method therefor |
US20040063685A1 (en) | 2000-12-08 | 2004-04-01 | Juji Ilzawa | Combination Drugs |
JP5137289B2 (ja) | 2001-08-03 | 2013-02-06 | 武田薬品工業株式会社 | 安定な乳化組成物 |
EP2366389A1 (en) | 2002-04-08 | 2011-09-21 | Takeda Pharmaceutical Company Limited | Severe sepsis preventive therapeutic agent |
US8710095B2 (en) | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
US20040259790A1 (en) | 2003-01-30 | 2004-12-23 | Bali Pulendran | Methods for identifying and administering agents that bias the immune response via dendritic cells |
US7485432B2 (en) | 2003-02-27 | 2009-02-03 | 3M Innovative Properties Company | Selective modulation of TLR-mediated biological activity |
EP1613956A2 (en) | 2003-03-25 | 2006-01-11 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
EP1664342A4 (en) | 2003-09-17 | 2007-12-26 | 3M Innovative Properties Co | SELECTIVE MODULATION OF TLR GENE EXPRESSION |
WO2005062854A2 (en) | 2003-12-19 | 2005-07-14 | University Of Cincinnati | Polyamides for nucleic acid delivery |
TWI462745B (zh) | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
NZ563863A (en) | 2005-06-03 | 2011-02-25 | Ono Pharmaceutical Co | Agent for regeneration and/or protection of nerves |
US7618982B2 (en) | 2005-12-19 | 2009-11-17 | Nerviano Medical Sciences S.R.L. | Heteroarylpyrrolopyridinones active as kinase inhibitors |
US20090175835A1 (en) | 2006-02-07 | 2009-07-09 | Korea Institute Of Radiological & Medical Sciences | Composition for treating damage of central or peripheral nerve system |
EP1996935B1 (en) | 2006-02-23 | 2011-09-14 | Yale University | Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway |
US7943588B2 (en) | 2006-03-28 | 2011-05-17 | Trustees Of Dartmouth College | Method for preventing or treating neuropathic pain |
EP1997902B1 (en) | 2006-03-30 | 2013-09-18 | Hiroshima University | Screening method |
JPWO2007123186A1 (ja) * | 2006-04-20 | 2009-09-03 | 武田薬品工業株式会社 | 医薬 |
EP2018855A1 (en) | 2006-05-15 | 2009-01-28 | Takeda Pharmaceutical Company Limited | Pharmaceutical agent |
WO2008004673A1 (fr) | 2006-07-07 | 2008-01-10 | Takeda Pharmaceutical Company Limited | Dérives de cycloalkène, procédé de production des dérivés et utilisation de ceux-ci |
EP1882687A1 (en) * | 2006-07-27 | 2008-01-30 | Amorepacific Corporation | Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same |
WO2008112887A1 (en) | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
US8399421B2 (en) | 2007-03-30 | 2013-03-19 | The Board Of Regents Of The University Of Texas System | Treatment for neuropathic pain due to spinal cord injury |
WO2009059050A2 (en) | 2007-10-30 | 2009-05-07 | The Regents Of The University Of Colorado | Tlr modulators and methods for using the same |
JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
JP5238381B2 (ja) | 2008-07-07 | 2013-07-17 | スタンレー電気株式会社 | 照明用車両用灯具 |
DK2480536T3 (da) | 2009-09-23 | 2014-10-27 | Univ Colorado Regents | Toll-lignende receptormodulatorer og anvendelser deraf |
-
2011
- 2011-01-26 WO PCT/JP2011/052077 patent/WO2011093512A1/en active Application Filing
- 2011-01-26 EA EA201290697A patent/EA201290697A1/ru unknown
- 2011-01-26 KR KR1020127021846A patent/KR20120118044A/ko active IP Right Grant
- 2011-01-26 PE PE2012001062A patent/PE20121694A1/es not_active Application Discontinuation
- 2011-01-26 CA CA2788150A patent/CA2788150C/en not_active Expired - Fee Related
- 2011-01-26 DK DK11705047.6T patent/DK2528598T3/en active
- 2011-01-26 UA UAA201210137A patent/UA109540C2/uk unknown
- 2011-01-26 GE GEAP201112845A patent/GEP20166441B/en unknown
- 2011-01-26 ME MEP-2016-31A patent/ME02364B/me unknown
- 2011-01-26 HU HUE11705047A patent/HUE027310T2/en unknown
- 2011-01-26 NZ NZ601635A patent/NZ601635A/xx not_active IP Right Cessation
- 2011-01-26 MX MX2012008514A patent/MX2012008514A/es not_active Application Discontinuation
- 2011-01-26 SI SI201130755T patent/SI2528598T1/sl unknown
- 2011-01-26 CN CN201180015681.3A patent/CN102821763B/zh not_active Expired - Fee Related
- 2011-01-26 ES ES11705047.6T patent/ES2560215T3/es active Active
- 2011-01-26 TW TW100102774A patent/TWI481401B/zh not_active IP Right Cessation
- 2011-01-26 RS RS20160076A patent/RS54591B1/en unknown
- 2011-01-26 EP EP11705047.6A patent/EP2528598B1/en active Active
- 2011-01-26 UY UY0001033203A patent/UY33203A/es not_active Application Discontinuation
- 2011-01-26 SG SG10201503402XA patent/SG10201503402XA/en unknown
- 2011-01-26 AR ARP110100247A patent/AR080024A1/es unknown
- 2011-01-26 MA MA35162A patent/MA34014B1/fr unknown
- 2011-01-26 CN CN201510072433.2A patent/CN104744321A/zh active Pending
- 2011-01-26 PT PT117050476T patent/PT2528598E/pt unknown
- 2011-01-26 BR BR112012018434A patent/BR112012018434A2/pt not_active IP Right Cessation
- 2011-01-26 JP JP2012533416A patent/JP6131046B2/ja active Active
- 2011-01-26 PL PL11705047T patent/PL2528598T3/pl unknown
- 2011-01-26 US US13/574,848 patent/US20130046000A1/en not_active Abandoned
- 2011-01-26 AU AU2011211294A patent/AU2011211294B2/en not_active Ceased
- 2011-01-26 SG SG2012051967A patent/SG182522A1/en unknown
- 2011-01-26 MY MYPI2012003414A patent/MY163936A/en unknown
-
2012
- 2012-07-17 TN TNP2012000364A patent/TN2012000364A1/en unknown
- 2012-07-23 IL IL221066A patent/IL221066A/en not_active IP Right Cessation
- 2012-07-25 DO DO2012000209A patent/DOP2012000209A/es unknown
- 2012-07-26 CL CL2012002079A patent/CL2012002079A1/es unknown
- 2012-07-27 ZA ZA2012/05681A patent/ZA201205681B/en unknown
- 2012-08-07 CR CR20120412A patent/CR20120412A/es unknown
- 2012-08-17 CO CO12140288A patent/CO6592110A2/es not_active Application Discontinuation
- 2012-08-27 EC ECSP12012126 patent/ECSP12012126A/es unknown
-
2013
- 2013-04-10 HK HK13104374.3A patent/HK1177423A1/zh not_active IP Right Cessation
- 2013-08-20 US US13/971,159 patent/US8901171B2/en not_active Expired - Fee Related
-
2014
- 2014-10-28 US US14/525,576 patent/US20150051256A1/en not_active Abandoned
-
2015
- 2015-04-02 US US14/676,947 patent/US20150203464A1/en not_active Abandoned
-
2016
- 2016-02-15 HR HRP20160165TT patent/HRP20160165T1/hr unknown
- 2016-02-19 US US15/047,965 patent/US20160166526A1/en not_active Abandoned
- 2016-03-04 CY CY20161100189T patent/CY1117268T1/el unknown
- 2016-03-18 JP JP2016056186A patent/JP2016175903A/ja active Pending
- 2016-04-12 SM SM201600103T patent/SMT201600103B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL233154A0 (en) | compounds | |
GB201109763D0 (en) | Compounds | |
GB201106395D0 (en) | Compounds | |
ZA201306857B (en) | Mesogen-containing compounds | |
HRP20160165T1 (hr) | Spojevi za suzbijanje poremeä†aja perifernog živca induciranog protutumorskim sredstvom | |
GB201008584D0 (en) | Novel iridium anti-cancer compounds | |
GB201122139D0 (en) | Compounds | |
GB201107197D0 (en) | Compounds | |
PL2799070T3 (pl) | Środek wzmacniający działanie środków przeciwnowotworowych | |
PL2581334T3 (pl) | Osłona przeciwwypadkowa dla urządzeń dźwigowych | |
EP2699237A4 (en) | THERAPY FOR LEUKEMIA | |
HK1191326A1 (en) | Azaspirodecanone compounds | |
GB201110107D0 (en) | Print gap compensation | |
GB201110938D0 (en) | Compounds | |
GB201105659D0 (en) | Compounds | |
GB201118613D0 (en) | Compounds | |
GB201015784D0 (en) | Anti-cancer compounds | |
AU2011900098A0 (en) | Cyclopropylbenzopyran compounds as anti-cancer agents | |
GB201000771D0 (en) | Compound for therapy | |
GB201121386D0 (en) | Protecting papers for toilets | |
AU2011094V (en) | HF001 Hymenosporum flavum | |
GB201015971D0 (en) | Cure for epilepsy | |
GB201114058D0 (en) | Cationic reactor | |
GB201120805D0 (en) | Compounds | |
GB201119703D0 (en) | Compounds |